PET/CT Response Criteria (European Organization for Research and Treatment of Cancer) Predict Survival Better Than Response Evaluation Criteria in Solid Tumors in Locally Advanced Cervical Cancer Treated With Chemoradiation

被引:13
作者
Yoon, Jung Won [1 ]
Kim, Sunghoon [1 ]
Kim, Sang Wun [1 ]
Kim, Young Tae [1 ]
Kang, Won Jun [2 ]
Nam, Eun Ji [1 ]
机构
[1] Yonsei Univ, Coll Med, Dept Obstet Gynecol, Womens Canc Clin,Inst Womens Life Med Sci, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Dept Nucl Med, Seongsan No 250,CPO Box 8044, Seoul 120752, South Korea
基金
新加坡国家研究基金会;
关键词
F-18-FDG; cervical cancer; CT; PET; POSITRON-EMISSION-TOMOGRAPHY; F-18; FLUORODEOXYGLUCOSE; METABOLIC-RESPONSE; RADIATION-THERAPY; ASSOCIATION; CARCINOMA; INDICATOR; PROGNOSIS; PATTERNS;
D O I
10.1097/RLU.0000000000001269
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To investigate whether the ratio of SUVs measured with F-18-FDG PET/CT between pretreatment and posttreatment has prognostic value in patients with locally advanced cervical cancer treated with primary chemoradiation therapy. Methods: Cases of locally advanced cervical cancer (International Federation of Gynecology and Obstetrics stages IB1 to IVA) treated with a nonsurgical curative modality (172 cases including chemoradiation or radiation therapy) were reviewed. F-18-FDG PET/CT parameters, including SUVmax and SUVmean, were evaluated by F-18-FDG PET/CT performed prior to treatment and 6 weeks after the end of treatment. Metabolic response was evaluated according to the European Organization for Research and Treatment of Cancer guidelines and was compared with radiologic response measured according to the Response Evaluation Criteria In Solid Tumours (RECIST). Results: In total, 142 patients receiving chemoradiation showed radiologic responses (median 56% decrease in maximal diameter), whereas 160 and 146 patients showed metabolic responses measured with SUVmax and SUVmean, respectively (73% decrease in SUVmax; 48% decrease in SUVmean). Radiologic response and metabolic response were significantly correlated for SUVmax and SUVmean (P = 0.0009; P = 0.0457, respectively). Kaplan-Meier analysis revealed significant differences in overall survival and progression-free survival between the responder and nonresponder groups, based on the European Organization for Research and Treatment of Cancer criteria (both P < 0.001), whereas no significant difference was found when using RECIST criteria (P = 0.058, P = 0.088, respectively). Conclusions: F-18-FDG PET/CT parameters are good prognostic markers for the response of cervical cancer patients to concurrent chemoradiation therapy, as compared with the RECIST criteria.
引用
收藏
页码:677 / 682
页数:6
相关论文
共 23 条
  • [1] Complete metabolic response after definitive radiation therapy for cervical cancer: Patterns and factors predicting for recurrence
    Beriwal, Sushil
    Kannan, Neeta
    Sukumyanich, Paniti
    Richard, Scott D.
    Kelley, Joseph L.
    Edwards, Robert P.
    Olawaiye, Alexander
    Krivak, Thomas C.
    [J]. GYNECOLOGIC ONCOLOGY, 2012, 127 (02) : 303 - 306
  • [2] The Role of 18 F-FDG PET/CT in Assessing Therapy Response in Cervix Cancer after Concurrent Chemoradiation Therapy
    Choi J.
    Kim H.J.
    Jeong Y.H.
    Lee J.-H.
    Cho A.
    Yun M.
    Lee J.D.
    Kim Y.B.
    Kim Y.T.
    Kang W.J.
    [J]. Nuclear Medicine and Molecular Imaging, 2014, 48 (2) : 130 - 136
  • [3] Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer
    Chung, Hyun Hoon
    Kim, Jae Weon
    Han, Kyung Hee
    Eo, Jae Seon
    Kang, Keon Wook
    Park, Noh-Hyun
    Song, Yong-Sang
    Chung, June-Key
    Kang, Soon-Beom
    [J]. GYNECOLOGIC ONCOLOGY, 2011, 120 (02) : 270 - 274
  • [4] Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of radiation therapy oncology group trial (RTOG) 90-01
    Eifel, PJ
    Winter, K
    Morris, M
    Levenback, C
    Grigsby, PW
    Cooper, J
    Rotman, M
    Gershenson, D
    Mutch, DG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) : 872 - 880
  • [5] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
  • [6] FLUORODEOXYGLUCOSE PET OF ABDOMINAL AND PELVIC NEOPLASMS - POTENTIAL ROLE IN ONCOLOGIC IMAGING
    GOLDBERG, MA
    LEE, MJ
    FISCHMAN, AJ
    MUELLER, PR
    ALPERT, NM
    THRALL, JH
    [J]. RADIOGRAPHICS, 1993, 13 (05) : 1047 - 1062
  • [7] The prognostic value of PET and PET/CT in cervical cancer
    Grigsby, Perry W.
    [J]. CANCER IMAGING, 2008, 8 (01): : 146 - 155
  • [8] Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix:: Response and outcome
    Grigsby, PW
    Siegel, BA
    Dehdashti, F
    Rader, J
    Zoberi, I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) : 2167 - 2171
  • [9] The role of PET/CT in cervical cancer
    Herrera, Fernanda G.
    Prior, John O.
    [J]. FRONTIERS IN ONCOLOGY, 2013, 3
  • [10] Radiology in invasive cervical cancer
    Hricak, H
    Yu, KK
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 1996, 167 (05) : 1101 - 1108